Logo

uniQure Reports 52-Week Clinical Data of Etranacogene Dezaparvovec in P-III HOPE-B Trial for Hemophilia B

Share this
uniQure Reports 52-Week Clinical Data of Etranacogene Dezaparvovec in P-III HOPE-B Trial for Hemophilia B

uniQure Reports 52-Week Clinical Data of Etranacogene Dezaparvovec in P-III HOPE-B Trial for Hemophilia B

Shots:

  • The P- III HOPE-B gene therapy trial involves assessing etranacogene dezaparvovec in 54 patients with severe and moderately hemophilia B
  • The results showed that the patients achieved sustained increases in FIX activity @ 1 yr. post-infusion with a mean FIX activity of 41.5% compared to 39.0% @ 26-wks of follow-up- reduced the ABR by 80% from 3.39 at baseline to 0.68 bleeds & 85% from 1.16 at baseline to 0.18 bleeds/yr from single-dose @ 1 yr. & generally well-tolerated with no treatment-related AEs
  • uniQure to conduct 1EPs analysis of ABR @78 wks. after the administration and expects to complete at the end of Q3’21 while UniQure & CSL Behring expects to submit the BLA in Q1’22

  | Ref: Globe Newswire | Image: Het Financieele Dagblad

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions